You are here

  • Home
  • Archive
  • Volume 8, Issue Suppl 10
  • PA-372 Evaluation of the prevention of mother-to-child transmission of HIV programs at the second immunization visit in Burkina Faso and Zambia, countries with different HIV epidemics

Article Text

Article menu

Download PDFPDF

Abstracts of Poster and e-Poster Presentations
PA-372 Evaluation of the prevention of mother-to-child transmission of HIV programs at the second immunization visit in Burkina Faso and Zambia, countries with different HIV epidemics
Free
  1. Souleymane Tassembedo1,
  2. Mwiya Mwiya2,
  3. Anais Mennecier3,
  4. Chipepo Kankasa2,
  5. Paulin Fao1,
  6. Jean Pierre Molès3,
  7. Dramane Kania1,
  8. Catherine Chunda-Liyoka2,
  9. Leticia Delphne Sakana1,
  10. Morgana D’Ottavi3,
  11. David Rutagwera2,
  12. Wilfried Tonga2,
  13. Thorkild Tylleskär4,
  14. Nicolas Nagot3,
  15. Philippe Van de Perre3,
  16. The PROMISE Study Group1,2,3,4
  1. 1Centre Muraz/National Institute of Public Health, Burkina Faso
  2. 2Pathogenesis and Control of Chronic and Emerging Infections, Montpellier University, INSERM, EFS, France
  3. 3Children’s Hospital, University Teaching Hospitals, Zambia
  4. 4Centre for International Health, Department of Global Public Health and Primary Care, University of Bergen, Norway

Abstract

Background Monitoring indicators for prevention of mother-to-child transmission of HIV programs (PMTCT) is key to assessing the progress toward elimination of mother-to-child transmission (MTCT) of HIV. Using a patient-orientated innovative strategy based on the second visit in the expanded program on immunization (EPI-2) visit at 6–8 weeks, we assessed PMTCT indicators in Burkina Faso and Zambia.

Methods From December 2019 to September 2021, the PROMISE-EPI study (Clinical Trial: NCT03870438) assessed women attending EPI-2 at primary health care facilities in Burkina Faso and Zambia with their children about their exposure to PMTCT interventions. Women living with HIV viral load was measured using GeneXpert® HIV RNA, and their children were tested for HIV using GeneXpert® HIV Qual.

Results Overall, 25093 were enrolled from Burkina Faso and 8961 women from Zambia. Almost, all women attended at least one antenatal care visit, the median number of visits was 4 (IQR: 3–5) in both countries. Among Women diagnosed with HIV at EPI-2, 4.5% and 1.7% were not aware of their HIV status, in Burkina Faso and Zambia, respectively. Among those aware of their HIV positive status, 95.8% and 99.2% were on ART in Burkina Faso and Zambia respectively. Among WLHIV on ART, 75% and 79.2% achieved a viral load suppression (Viral load < 1000 copies/mL) in Burkina Faso and Zambia respectively. Infant post-natal prophylaxis was administered from birth until EPI-2 to 60.9% and 89.7% of HIV exposed children in Burkina Faso and Zambia, respectively. In Burkina Faso, only 60/192 (31.3%) of HIV exposed children were sampled for early infant diagnosis and 3 (1.6%) received a result by EPI-2. In Zambia, these figures were 879/1465 (64.0%) and 9.9% (145/1465) respectively.

Conclusion This evaluation strategy could strengthen program monitoring and help identifying gaps to be addressed on the last mile towards elimination of MTCT of HIV.

https://doi.org/10.1136/bmjgh-2023-EDC.173

Statistics from Altmetric.com

    Request Permissions

    If you wish to reuse any or all of this article please use the link below which will take you to the Copyright Clearance Center’s RightsLink service. You will be able to get a quick price and instant permission to reuse the content in many different ways.